Anaphylactic Shock After Intravenous Administration of Indocyanine Green During Robotic Partial Nephrectomy

William Chua, Avinash Chennamsetty, Robert Toroussian, Clayton Lau

City of Hope National Medical Center, Department of Urology and Urologic Oncology, Duarte, CA, USA

City of Hope National Medical Center, Department of Anesthesia, Duarte, CA, USA

Abstract

Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe. However, there are reported cases of severe complications from ICG when used for non-urologic purposes. We present the first case to our knowledge of anaphylactic shock in response to intravenous ICG during a robotic partial nephrectomy.

Introduction

ICG, a sterile US Food and Drug Administration-approved water-soluble dye, is a popular diagnostic reagent that has been in clinical use for the examination of hepatic function, ophthalmic angiography, cardiac output and circulating blood volume. With the advent of robotic-assisted laparoscopic surgery and near-infrared fluorescence (NIRF) lenses, ICG has found several applications in Urologic surgery including ureteral identification, differentiation of tumors from normal parenchyma and as a lymphangiography agent.

Intravenous (IV) ICG has had a long record of safety for over 50 years with previous reports of mostly low-grade complications. We report the first case of anaphylactic shock following IV administration of ICG during a robotic-assisted partial nephrectomy.

Case presentation

A 53-year-old, 90-kg male was incidentally diagnosed with a left interpolar 2.2 cm × 2.3 cm × 2.2 cm renal mass (cT1a, Stage 1) on imaging following a penetrating abdominal trauma. Patient denied any constitutional symptoms (fevers, night sweats or weight loss) and had no pertinent physical exam findings.

Past medical history was significant for coronary artery disease with prior myocardial infarction, hypertension, and insulin-dependent diabetes mellitus. He had no prior anesthetic complications, nor allergies to food, iodinated contrast, or medications. He demonstrated good performance status and cardiopulmonary evaluation revealed normal findings. A beta-blocker was started 1 week prior to surgery.

The patient underwent uneventful anesthesia induction, and the case proceeded with a robotic-assisted transperitoneal approach. Prior to clamping the renal hilum, IV mannitol 12.5 g and ICG 5 mg were given. Shortly after, the patient developed increased peak airway pressures, severe hypotension and ventricular tachycardia. The ET tube and depth of anesthesia were confirmed. Epinephrine and phenylephrine were administered and IV fluids were increased.

After the patient failed to respond, the robot was undocked and the patient repositioned supine. A weak pulse was palpated and chest compressions were initiated. The patient underwent successful cardioversion with return to sinus rhythm and an improvement in hypotension. After the patient stabilized for an appropriate period, the operation was completed without further issue (estimated blood loss was 100 mL and 5 L IV fluids administered with warm ischemia time of 28 min). Serologic tests including cardiac enzymes and C3/IgE were within normal limits. However, serum tryptase was elevated at 56.7 μg/L (reference < 10.9 μg/L). The remaining course was uneventful and the patient was discharged on post-operative day two. Final pathology revealed a pT1aNxMxR0 clear cell renal cell carcinoma, Fuhrman grade three.
attributed to anaphylaxis. Obana et al similarly reported on a large series of IV or intradermal ICG video angiography cases (3774 cases performed on 2820 patients). Incidence of adverse reaction was only 0.34%, the majority of which were mild. However, two patients experienced hypotension. Notably the dose of ICG varied from 25 to 75 mg, which is much higher than the typically used for robotic surgery. Bjerregaard et al described two cases of severe hypotension following IV ICG administered (5 mg and 2.5 mg respectively) during neurovascular procedures.

We describe, the first of our knowledge, a case of a life-threatening anaphylaxis following IV ICG during a robotic urologic surgery. We believe our case to be consistent with an anaphylactic response to ICG for several reasons. First, the timing of the patient’s acute changes following IV ICG corroborates a medication response. Second, while there are other causes of increased peak airway pressures, our patient developed a rapid constellation of findings including hypotension and ventricular tachycardia. Also, the position of the endotracheal tube and appropriate depth of anesthesia were confirmed. The patient was also placed supine and the abdomen was desulfated in the event that the surgical positioning or pneumoperitoneum were contributing to isolated bronchospasm. There was also no significant blood loss to account for the acute changes. Third, the markedly increased postoperative serum tryptase level, a serum protease secreted by mast cells used to assess for anaphylaxis, supports the diagnosis of anaphylaxis.

It has been proposed that systemic reactions from ICG may be attributable to the iodide component. However, the physiology of these reactions remain unknown as cases of adverse events have been documented in iodide-free preparations of ICG. Further, ICG has been used safely in patients with recorded iodine allergies. In addition, there is no known dose threshold below for an ICG adverse reaction as seen in our case in which a single small dose (5 mg IV) was given. As the mechanism behind ICG reactions remains unknown, currently there is no way to predict who will experience an ICG-related complication. Skin or low dose IV testing for ICG allergy has not proven useful.

Conclusion

We report the first episode of anaphylactic response to ICG in the contemporary robotic surgical era. While ICG-related complications are rare, the vulnerable population remains unknown and Urologists should be familiar with this complication.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

No acknowledgements.

References

1. Hope-Ross M, Vannuzzi LA, Gragoudas ES, et al. Adverse reactions due to indocyanine green. Ophthalmolog. 1994;101:529–533.
2. Obana A, Miki T, Hayashi K, et al. Survey of complications of indocyanine green injection during the intraoperative period. Am J Ophthalmol. 1994;118:749–753.
3. Bjerregaard J, Pandia MP, Jaffe RA. Occurrence of severe hypotension after indocyanine green injection during the intraoperative period. A A Case Rep. 2013;1:26–30.
4. Brown SG, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australas. 2004;16(2):120–124.
5. Bonte CA, Couppens J, Leys AM. Hypotensive shock as a complication of indocyanine green injection. Retina. 1998;18:476–477.